NYSE · ALUR.WS

Allurion Technologies, Inc.. , each whole exercisable to purchase 0. 056818 of at an exercise price of $202. 50 per of

$0.01 -$0.00 (-4.80%) 1D
Session Pulse Regular session 1 mentions on Fri No new SEC filings since Mon close its sector ranked 5/11 this week Full pulse →
Charting by TradingView

Key Metrics

$56.86K
Market cap
—
P/E · TTM
$12.60M
Revenue · TTM
−$33.35M
Net income
EPS · TTM $-6.98
Dividend yield —
Free cash flow —
Beta · 1Y -1.48
EBITDA · TTM −$32.35M
Gross margin 52.7%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    A material event was filed (Form 8-K).

    8-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 23
    A material event was filed (Form 8-K).

    8-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap—
Enterprise value−$5.00M
Shares outstanding—
52-wk range$0.00 – $0.06
Avg volume · 20D42.6K
Net cash $5.06M
Book value / share$-16.30
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNYSE
About Allurion Technologies, Inc.. , each whole exercisable to purchase 0. 056818 of at an exercise price of $202. 50 per of
IPO dateAug 2, 2023
Employees137

Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E—
P/S0.00
P/FCF—
EV/EBITDA—
EV/Sales-0.40
Graham №—

Profitability

Gross 52.7%
Operating -264.7%
Net -264.7%
FCF —
ROE / ROIC 42.8% · 40.2%

Financial Health

Current ratio0.30
Quick ratio0.25
Debt / equity0.00
Debt / EBITDA 0.00Low leverage
Net cash $5.06M
Working capital−$25.95M

Cash Flow · TTM

Operating CF −$22.70M
Capex —
Free cash flow —
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

-34.9
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings